Company Overview and News
In a pyrrhic victory, akin to Luke Skywalker escaping Cloud City in Empire Strikes Back despite having his arm cut off, the Alerian MLP Index finished positive for the week by 0.2%. The equal weight v
I recently wrote a controversial piece on Ferrellgas Partners' distribution.I have some time on the train today, so I decided to follow up on the name and looked over some SEC filings.I report breakin
On Nov 28, Zacks Investment Research downgraded Enerplus Corporation (ERF), an upstream energy player, to a Zacks Rank #5 (Strong Sell).
In the week ended September 11, US propane inventories rose 1.1 MMbbls to 97.7 MMbbls. These levels are 20.3 MMbbls greater, or 26.2% higher, than they were in the corresponding period last year.
In the week ending September 25, US propane inventories rose by 1.7 MMbbls to 98.7 MMbbls—a 24.1% increase from the corresponding period last year.
In the week ended October 9, 2015, US propane inventories rose by 1.8 MMbbls (million barrels) to 102.2 MMbbls.
Propane production is outstripping demand by a considerable margin. This explains the steady build in propane inventories.
In the week ended September 4, US propane inventories rose 0.2 MMbbls to 96.6 MMbbls. These levels are 20.5 MMbbls greater, or 27% higher, than they were in the corresponding period last year.
In the week ended September 18, US propane inventories fell 0.6 MMbbls (million barrels) to 97.1 MMbbls. These levels are 18 MMbbls greater, or 22.7% higher, than they were in the corresponding period ...
In the week ended October 2, 2015, US propane inventories rose by 1.6 million barrels to 100.3 million barrels, levels 24.4% greater than in 2014.
In its Weekly Petroleum Status Report released on November 12, 2015, the EIA (U.S. Energy Information Administration) stated that US propane inventories rose by 1.6 million for the week ended November 6. That’s well above the upper limit of the average range.
Weather forecasts, which are calling for above ordinary temperatures over a large portion of the United States, will keep propane demand low.
Many commodities have further to fall.China's less obvious impact on commodities.Supply and demand aren't the only factors determining performance.Higher interest rates and stronger U.S. dollar will u
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...